Antibiotic Treatment for Streptococcus intermedius Pneumonia

First-Line Treatment Regimens

The Infectious Diseases Society of America recommends ampicillin 2g IV every 4-6 hours as the preferred agent for hospitalized patients with Streptococcus intermedius pneumonia, providing superior coverage against this organism compared to broader-spectrum agents 1, 2
For severe pneumonia, the American Thoracic Society suggests ampicillin 2g IV every 4 hours plus azithromycin 500mg IV daily as mandatory combination therapy 3, 4
Ceftriaxone 2g IV daily is an acceptable alternative β-lactam if ampicillin is unavailable, though ampicillin/penicillin remain preferred for confirmed streptococcal infections 1, 2

For non-severe penicillin allergy, the American Academy of Otolaryngology-Head and Neck Surgery recommends ceftriaxone 1-2g IV daily plus azithromycin 500mg daily as the preferred regimen, due to low cross-reactivity with third-generation cephalosporins 5, 6
For severe penicillin allergy, the Infectious Diseases Society of America suggests levofloxacin 750mg IV daily as monotherapy, providing excellent coverage for S. intermedius without β-lactam exposure 3, 4

The American Thoracic Society recommends extending treatment duration to 14-21 days if complicated by empyema or abscess, rather than the standard 5-7 days for uncomplicated pneumonia 3, 4
The Infectious Diseases Society of America suggests switching to oral amoxicillin 1g three times daily when hemodynamically stable, afebrile for 24-48 hours, and able to tolerate oral intake 4
For penicillin-allergic patients, the American College of Chest Physicians recommends transitioning to oral levofloxacin 750mg daily or moxifloxacin 400mg daily 3, 4

The Infectious Diseases Society of America advises against using macrolide monotherapy for S. intermedius pneumonia, as β-lactam coverage is essential and macrolides provide inadequate gram-positive coverage 4
The American Thoracic Society recommends avoiding empiric vancomycin or linezolid unless MRSA risk factors are present, as S. intermedius remains penicillin-sensitive 7, 8
The Infectious Diseases Society of America suggests obtaining blood cultures and considering pleural fluid sampling before initiating antibiotics in all hospitalized patients, as S. intermedius frequently causes bacteremia and empyema requiring source control 3, 4